| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -506,005 | -468,005 |
| Depreciation | 10,251 | 7,790 |
| Amortization of intangible assets | 368,429 | 367,409 |
| Amortization of right-of-use assets | 3,083 | 2,162 |
| Share-based compensation expense | 32,080 | 21,096 |
| Impairment charges | 15,000 | 15,000 |
| Accretion of discount and amortization of premium on marketable securities, net | 3,905 | 2,982 |
| Change in the estimated fair value of contingent consideration | -18,700 | -18,700 |
| Inventory provision | 9,768 | 8,542 |
| Deferred income taxes | -546 | -546 |
| Other | -1,456 | -1,059 |
| Accounts receivable, net | 3,092 | 4,733 |
| Inventory, net | 4,926 | 3,868 |
| Prepaid expenses and other assets | -7,797 | -6,809 |
| Accounts payable | 761 | -505 |
| Accrued expenses | -1,396 | -2,407 |
| Deferred revenue | 685 | 808 |
| Operating lease liabilities | -661 | -1,730 |
| Other liabilities | -2,219 | -632 |
| Net cash used in operating activities | -92,140 | -73,433 |
| Purchases of property and equipment | 1,853 | 1,939 |
| Purchases of intangible assets | 5,000 | 5,000 |
| Purchases of investments | 183,817 | 117,992 |
| Sales of investments | 0 | - |
| Maturities of investments | 280,089 | 195,448 |
| Net cash provided by investing activities | 89,419 | 70,517 |
| Proceeds from issuance of common stock from equity plans | 3,428 | 1,959 |
| Notes payable principal payoff | 0 | 0 |
| Net cash provided by financing activities | 3,428 | 1,959 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 707 | -957 |
| Cash and cash equivalents at beginning of period | 57,592 | - |
| Cash and cash equivalents at end of period | 58,299 | - |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)